Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Protara Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, DEC. 08, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC. (NASDAQ: TARA) (PROTARA), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCED THE CLOSING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 13,043,479 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $5.75 PER SHARE. IN ADDITION, PROTARA HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 1,956,521 SHARES OF COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE GROSS PROCEEDS FROM THE OFFERING WERE APPROXIMATELY $75 MILLION BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES PAYABLE BY PROTARA AND EXCLUDING ANY EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES. PROTARA INTENDS TO USE THE NET PROCEEDS RECEIVED FROM THE OFFERING TO FUND THE CLINICAL DEVELOPMENT OF TARA-002, AS WELL AS THE DEVELOPMENT OF OTHER CLINICAL PROGRAMS. PROTARA MAY ALSO USE THE NET PROCEEDS FROM THE OFFERING FOR WORKING CAPITAL AND OTHER GENERAL CORPORATE PURPOSES.

PROTARA ANNOUNCES CLOSING OF $75 MILLION PUBLIC OFFERING

NEW YORK, DEC. 04, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC. (NASDAQ: TARA) (PROTARA), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCED THE PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 13,043,479 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $5.75 PER SHARE. IN ADDITION, PROTARA HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 1,956,521 SHARES OF COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. ALL SHARES IN THE OFFERING ARE BEING SOLD BY PROTARA. THE GROSS PROCEEDS FROM THE OFFERING ARE EXPECTED TO BE APPROXIMATELY $75 MILLION BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES PAYABLE BY PROTARA AND EXCLUDING ANY EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES. THE OFFERING IS EXPECTED TO CLOSE ON DECEMBER 8, 2025, SUBJECT TO SATISFACTION OF CUSTOMARY CLOSING CONDITIONS. PROTARA INTENDS TO USE THE NET PROCEEDS RECEIVED FROM THE OFFERING TO FUND THE CLINICAL DEVELOPMENT OF TARA-002, AS WELL AS THE DEVELOPMENT OF OTHER CLINICAL PROGRAMS. PROTARA MAY ALSO USE THE NET PROCEEDS FROM THE OFFERING FOR WORKING CAPITAL AND OTHER GENERAL CORPORATE PURPOSES.

PROTARA ANNOUNCES PRICING OF $75 MILLION PUBLIC OFFERING

NEW YORK, DEC. 04, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC. (NASDAQ: TARA) (PROTARA), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $75 MILLION IN AGGREGATE OF SHARES OF ITS COMMON STOCK OR, IN LIEU OF ISSUING COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK. ALL OF THE SHARES OF COMMON STOCK AND PRE-FUNDED WARRANTS TO BE SOLD IN THE PROPOSED OFFERING WILL BE OFFERED BY PROTARA. IN ADDITION, PROTARA EXPECTS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE ADDITIONAL SHARES OF COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE PROPOSED OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR THE ACTUAL SIZE OR TERMS OF THE OFFERING. PROTARA INTENDS TO USE THE NET PROCEEDS RECEIVED FROM THE OFFERING TO FUND THE CLINICAL DEVELOPMENT OF TARA-002, AS WELL AS THE DEVELOPMENT OF OTHER CLINICAL PROGRAMS. PROTARA MAY ALSO USE THE NET PROCEEDS FROM THE OFFERING FOR WORKING CAPITAL AND OTHER GENERAL CORPORATE PURPOSES.

PROTARA ANNOUNCES PROPOSED PUBLIC OFFERING

TARA-002 DEMONSTRATES 72% COMPLETE RESPONSE RATE AT ANY TIME IN BCG-NAVE PATIENTS TARA-002 DEMONSTRATES A 69% COMPLETE RESPONSE RATE AT THE 6-MONTH LANDMARK AND A 50% COMPLETE RESPONSE RATE AT THE 12-MONTH LANDMARK IN BCG-NAVE PATIENTS FAVORABLE SAFETY AND TOLERABILITY PROFILE OBSERVED WITH NO GRADE 3 OR GREATER TREATMENT-RELATED ADVERSE EVENTS REPORTED COMPANY OBTAINED WRITTEN FEEDBACK FROM FDA ON REGISTRATIONAL PATH FORWARD FOR TARA-002 IN BCG-NAVE PATIENTS COMPANY REMAINS ON TRACK TO REPORT INTERIM RESULTS FROM APPROXIMATELY 25 SIX-MONTH EVALUABLE BCG-UNRESPONSIVE PATIENTS IN THE REGISTRATIONAL COHORT OF THE ADVANCED-2 TRIAL IN Q1 2026 COMPANY EXPECTS TO COMPLETE ENROLLMENT OF THE BCG-UNRESPONSIVE REGISTRATIONAL COHORT OF THE ADVANCED-2 TRIAL IN 2H 2026 COMPANY TO HOST CONFERENCE CALL AND WEBCAST TODAY AT 8:30 A.M. ET NEW YORK, DEC. 03, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC. (NASDAQ: TARA), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCED UPDATED INTERIM DATA FROM THE ONGOING PHASE 2 OPEN-LABEL ADVANCED-2 TRIAL OF TARA-002 IN PATIENTS WITH CARCINOMA IN SITU OR CIS ( TA/T1) NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC).

PROTARA THERAPEUTICS ANNOUNCES UPDATED INTERIM DATA FROM PHASE 2 ADVANCED-2 TRIAL OF TARA-002 IN BCG-NAVE NMIBC PATIENTS

NEW YORK, DEC. 01, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC. (NASDAQ: TARA), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCED THAT IT WILL HOST A CONFERENCE CALL AND LIVE WEBCAST AT 8:30 AM ET ON WEDNESDAY, DECEMBER 3, 2025, TO REVIEW NEW DATA FROM AN INTERIM ANALYSIS OF THE ONGOING PHASE 2 OPEN-LABEL ADVANCED-2 TRIAL OF TARA-002 IN BCG-NAVE PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC). THE DATA WILL BE FEATURED DURING A POSTER SESSION AT THE 26TH ANNUAL MEETING OF THE SOCIETY OF UROLOGIC ONCOLOGY (SUO). THE COMPANY WILL ALSO PROVIDE AN UPDATE ON FEEDBACK FROM THE U.S. FOOD AND DRUG ADMINISTRATION ON A REGISTRATIONAL PATH FORWARD FOR TARA-002 IN BCG-NAVE PATIENTS.

PROTARA THERAPEUTICS TO HOST CONFERENCE CALL AND WEBCAST TO REVIEW NEW INTERIM DATA FROM PHASE 2 ADVANCED-2 TRIAL OF TARA-002 IN BCG-NAVE NMIBC PATIENTS ON WEDNESDAY, DECEMBER 3, 2025

80% OF PATIENTS THAT COMPLETED TREATMENT AND 100% OF PATIENTS THAT COMPLETED THE EIGHT-WEEK RESPONSE ASSESSMENT ACHIEVED CLINICAL SUCCESS CLINICAL SUCCESS ACHIEVED WITH ONE OR TWO DOSES OF TARA-002 IN 88% OF PATIENTS TARA-002 DEMONSTRATED FAVORABLE SAFETY AND TOLERABILITY PROFILE WITH NO SERIOUS ADVERSE EVENTS REPORTED COMPANY TO HOST CONFERENCE CALL AND WEBCAST FEATURING KEY OPINION LEADER DR. JESSE JONES AT 8:30 A.M. ET NEW YORK, NOV. 19, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC.(NASDAQ: TARA), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCED POSITIVE INTERIM RESULTS FROM ITS ONGOING PHASE 2 OPEN-LABEL STARBORN-1 TRIAL ASSESSING INTRACYSTIC INJECTION OF TARA-002, THE COMPANY'S INVESTIGATIONAL CELL-BASED THERAPY, IN PEDIATRIC PATIENTS WITH MACROCYSTIC AND MIXED CYSTIC LYMPHATIC MALFORMATIONS (LMS).

PROTARA THERAPEUTICS ANNOUNCES POSITIVE INTERIM RESULTS DEMONSTRATING ROBUST RESPONSES IN THE ONGOING PHASE 2 STARBORN-1 TRIAL OF TARA-002 IN PEDIATRIC PATIENTS WITH LYMPHATIC MALFORMATIONS

NEW YORK, NOV. 18, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC. (NASDAQ: TARA), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCED IT WILL HOST A CONFERENCE CALL AND LIVE WEBCAST AT 8:30 A.M. ET ON WEDNESDAY, NOVEMBER 19, 2025, TO REVIEW NEW DATA FROM AN INTERIM ANALYSIS OF THE ONGOING PHASE 2 OPEN-LABEL STARBORN-1 TRIAL ASSESSING TARA-002, THE COMPANY'S INVESTIGATIONAL CELL-BASED THERAPY, IN PEDIATRIC PATIENTS WITH MACROCYSTIC AND MIXED CYSTIC LYMPHATIC MALFORMATIONS (LMS).

PROTARA THERAPEUTICS TO HOST CONFERENCE CALL AND WEBCAST TO REVIEW NEW INTERIM DATA FROM PHASE 2 STARBORN-1 TRIAL OF TARA-002 IN PEDIATRIC PATIENTS WITH LYMPHATIC MALFORMATIONS ON WEDNESDAY, NOVEMBER 19, 2025

NEW YORK, NOV. 17, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC. (NASDAQ: TARA), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCED THAT INTERIM DATA FROM COHORT A OF THE ONGOING PHASE 2 OPEN-LABEL ADVANCED-2 TRIAL OF TARA-002 IN BCG-NAVE PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) WILL BE FEATURED DURING A POSTER SESSION AT THE UPCOMING 26TH ANNUAL MEETING OF THE SOCIETY OF UROLOGIC ONCOLOGY (SUO) TAKING PLACE FROM DECEMBER 2, 2025 TO DECEMBER 5, 2025, IN PHOENIX, ARIZONA. THE PRESENTATION WILL INCLUDE DATA FEATURED IN THE ABSTRACT PUBLISHED ON THESUO WEBSITE, AS WELL AS UPDATED SAFETY AND EFFICACY DATA FROM 31 ENROLLED BCG-NAVE PATIENTS, THE MAJORITY OF WHOM HAVE REACHED THE SIX-MONTH EVALUATION TIME POINT.

PROTARA THERAPEUTICS TO PRESENT NEW INTERIM DATA FROM PHASE 2 ADVANCED-2 TRIAL OF TARA-002 IN BCG-NAVE NMIBC PATIENTS AT THE 26TH ANNUAL MEETING OF THE SOCIETY OF UROLOGIC ONCOLOGY

RESULTS FROM AN INTERIM ANALYSIS IN THE PHASE 2 STARBORN-1 TRIAL OF TARA-002 IN PEDIATRIC LMS PATIENTS REMAIN ON TRACK FOR 4Q 2025 EXPECT TO PRESENT INTERIM ANALYSIS FROM APPROXIMATELY 25 SIX-MONTH EVALUABLE BCG-UNRESPONSIVE NMIBC PATIENTS IN THE ONGOING ADVANCED-2 TRIAL IN 1Q 2026 DOSING OF FIRST PATIENT IN THRIVE-3 REGISTRATIONAL TRIAL OF IV CHOLINE CHLORIDE IN PATIENTS DEPENDENT ON PARENTERAL SUPPORT NOW EXPECTED BY YEAR-END 2025 CASH, CASH EQUIVALENTS AND INVESTMENTS OFAPPROXIMATELY$134MILLIONAS OFSEPTEMBER 30, 2025, EXPECTED TO SUPPORT PLANNED OPERATIONS INTO MID-2027 NEW YORK, NOV. 10, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC. (NASDAQ: TARA) (PROTARA OR THE COMPANY), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED A BUSINESS UPDATE. WE HAVE MADE IMPORTANT ADVANCEMENTS ACROSS OUR CLINICAL PROGRAMS THIS YEAR, AND WITH MANY SIGNIFICANT MILESTONES IN THE NEAR FUTURE, WE REMAIN FOCUSED ON DISCIPLINED EXECUTION ACROSS OUR PIPELINE OF TRANSFORMATIVE THERAPIES FOR PATIENTS WITH CANCER AND RARE DISEASES, SAIDJESSE SHEFFERMAN, CHIEF EXECUTIVE OFFICER OFPROTARA THERAPEUTICS.

PROTARA THERAPEUTICS ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

NEW YORK, NOV. 04, 2025 (GLOBE NEWSWIRE) -- PROTARA THERAPEUTICS, INC.(NASDAQ: TARA), A CLINICAL-STAGE COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF CANCER AND RARE DISEASES, TODAY ANNOUNCED THAT IT HAS BEEN NAMED A BIOSPACE 2026 BEST PLACE TO WORK. PROTARA IS THRILLED TO BE RECOGNIZED AS ONE OF THE MOST SOUGHT-AFTER BIOTECH EMPLOYERS IN THE LIFE SCIENCES COMMUNITY, SAID JESSE SHEFFERMAN, CHIEF EXECUTIVE OFFICER OF PROTARA THERAPEUTICS.

Protara Therapeutics, Inc.

TARA

Price

Financial Reports

No items found.

Press Releases

Protara Therapeutics, Inc.

TARA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

TARA